Response to FOLFIRINOX by Gender in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ ACCORD 11 Randomized Trial

PLoS ONE - United States
doi 10.1371/journal.pone.0183288
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Systematic Review of FOLFIRINOX in Patients With Locally Unresectable Pancreatic Cancer

HPB
HepatologyGastroenterology
2016English

Cost-Effectiveness of FOLFIRINOX for First-Line Treatment of Metastatic Pancreatic Cancer.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Neoadjuvant FOLFIRINOX for Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis

Oncologist
Cancer ResearchMedicineOncology
2019English

Cost-Effectiveness of FOLFIRINOX for First-Line Treatment of Metastatic Pancreatic Cancer

Current Oncology
Oncology
2013English

Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
1999English

FOLFIRINOX in Patients With Peritoneal Carcinomatosis From Pancreatic Adenocarcinoma: A Retrospective Study

Current Oncology
Oncology
2019English

Smarter Lunchrooms Randomized Control Trial: Results From Year 4

Journal of Nutrition Education and Behavior
MedicineNutritionDietetics
2017English

Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine for First-Line Treatment of Patients With Metastatic Pancreatic Cancer From the US Societal Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy via Profiling Circulating Cell-Free DNA in Pancreatic Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy